Differentiation of human myeloid leukemia cell lines induced by tumor-promoting phorbol ester (TPA). I. Changes of the morphology, cytochemistry and the surface differentiation antigens analyzed with monoclonal antibodies.
Human myeloid leukemia cell lines ML-1, ML-2, ML-3, promyelocytic leukemia cell line HL-60 and histiocytic lymphoma cell line U-937 were induced to differentiate by 0.5-10 ng/ml (0.8-16 nM) 12-O-tetradecanoylphorbol-13-acetate (TPA). After 48-72 h of induction, changes of the morphology, cytochemistry and of the antigenic phenotype of induced and control cells were studied using a panel of monoclonal antibodies against granulocytic, monocytic, HLA-ABC and HLA-DR antigens in indirect immunofluorescence. Cells of the TPA-treated cultures acquired morphological, cytochemical and antigenic markers of monocytes/macrophages, as surface adherence, alpha-naphthyl acetate esterase (alpha-NE) and acid phosphatase activity and the expression of monocytic antigens detected with monoclonal antibodies 63D3, FMC 17, B 44.1, B 52.1 and anti-Mol. During differentiation in vitro induced by TPA, also loss of HLA-DR antigens and diminution of antigen of cell activation were detected with antibodies L 243 and 4F2. The expression of granulocytic antigens was only slightly diminished and the expression of HLA-ABC antigens was not changed by TPA-treatment. There were differences in the percentage of cells induced to differentiate among the lines of different origin and even among the lines ML-1, ML-2 and ML-3, established from a single patient with acute myeloid leukemia. After treatment of cultures with 5 ng/ml TPA for 72 h DNA synthesis was inhibited to 60-80%.
D000135:Acid Phosphatase / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000032:analysis*; D002265:Carboxylic Ester Hydrolases / Q000032:analysis*; D002454:Cell Differentiation; D002460:Cell Line; D005455:Fluorescent Antibody Technique; D006680:HLA Antigens / Q000032:analysis; D015234:HLA-A Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006651:Histocytochemistry; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000276:immunology / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced / Q000276:immunology / Q000473:pathology*; D009283:Naphthol AS D Esterase / Q000032:analysis*; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D006680:HLA Antigens; D015234:HLA-A Antigens; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D009283:Naphthol AS D Esterase; D002265:Carboxylic Ester Hydrolases; D000135:Acid Phosphatase; D013755:Tetradecanoylphorbol Acetate